Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Biotest AG
DescriptionHCV neutralizing polyclonal antibody
Molecular Target Not available
Mechanism of ActionBinds viral antigens
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsPrevent HCV infection in liver transplant patients; Prevent recurrence of hepatitis C-related liver disease in HCV positive liver transplant recipients or in patients who received an HCV-positive liver; Treat and prevent HCV infection
Regulatory Designation U.S. - Orphan Drug (Prevent HCV infection in liver transplant patients);
EU - Orphan Drug (Prevent HCV infection in liver transplant patients)
Partner Kedrion Group S.p.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today